At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 9 enrolled
Drug / intervention
lomitapidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy
In Brief
A Phase 3 clinical trial evaluating lomitapide for Familial Hypercholesterolemia - Homozygous. Completed, enrolled 9 participants across 6 sites.
Detailed Summary
Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedJun 2014
Primary CompletionApr 2015
Study CompletionDec 2015
TodayJul 2026
First PostedJun 24, 2014
Enrollment StartApr 2, 2014
Primary CompletionApr 3, 2015
Study CompletionDec 17, 2015
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 12.0 years ago
Interventions
lomitapidedrug